Despite several therapeutic advances over the past decade, multiple myeloma (MM)
remains largely incurable, indicating a need for new treatment approaches. Chimeric …

Infection remains the leading cause of morbidity and mortality in patients with multiple
myeloma because of the cumulative effect of disease, treatment, and host-related factors …

Abstract The European Conference on Infections in Leukaemia (ECIL) updated its
guidelines on antifungal prophylaxis for adults using the grading system of IDSA. The …

Antibody deficiency or hypogammaglobulinemia can have primary or secondary etiologies.
Primary antibody deficiency (PAD) is the result of intrinsic genetic defects, whereas …

Introduction: Chimeric antigen receptor T-cell therapy (CAR-T cell therapy) is a novel
immunotherapy with promising results in the treatment of relapsed or refractory B cell …

Multiple myeloma (MM) remains an incurable hematologic malignancy, despite the
development of numerous innovative therapies during the past two decades …

Background Patients with relapsed/refractory multiple myeloma are at increased risk of
infection. Infections during treatment with teclistamab, the first B‐cell maturation antigen …

During the last few years, several new drugs have been introduced for treatment of patients
with multiple myeloma, which have significantly improved treatment outcome. All of these …

Infections are a major cause of morbidity and mortality in multiple myeloma. The increased
risk for bacterial and viral infections results mainly from the disease‐inherent and treatment …

The role of infection and chronic inflammation in plasma cell disorders (PCD) has been well-
described. Despite not being a diagnostic criterion, infection is a common complication of …